Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:16:36 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:CTMX from 2023-05-04 to 2024-05-03 - 26 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 08:00U:CTMXNews ReleaseCytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
2024-04-08 08:00U:CTMXNews ReleaseCytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
2024-04-03 08:00U:CTMXNews ReleaseCytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY(TM) T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
2024-03-21 08:00U:CTMXNews ReleaseCytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
2024-03-18 08:00U:CTMXNews ReleaseCytomX Therapeutics Announces Milestone Achievement in PROBODY(TM) T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
2024-03-11 16:10U:CTMXNews ReleaseCytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
2024-03-04 08:00U:CTMXNews ReleaseCytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
2024-02-27 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present at Upcoming March Investor Conferences
2024-01-24 08:00U:CTMXNews ReleaseCytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody ‚ ® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
2024-01-12 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
2024-01-04 08:00U:CTMXNews ReleaseCytomX Therapeutics Outlines 2024 Company Priorities and Milestones
2023-12-21 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07 16:15U:CTMXNews ReleaseCytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-01 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present at Upcoming November Investor Conferences
2023-10-31 08:00U:CTMXNews ReleaseCytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
2023-10-30 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting
2023-10-18 16:30U:CTMXNews ReleaseCytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference
2023-09-05 16:05U:CTMXNews ReleaseCytomX Therapeutics to Present at Upcoming September Investor Conferences
2023-08-10 16:05U:CTMXNews ReleaseCytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
2023-08-08 16:15U:CTMXNews ReleaseCytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-08-01 08:00U:CTMXNews ReleaseCytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023
2023-07-20 09:00U:CTMXNews ReleaseCytomX Therapeutics Announces New Employment Inducement Grants
2023-07-17 08:00U:CTMXNews ReleaseCytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
2023-06-30 08:00U:CTMXNews ReleaseCytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.
2023-06-01 16:05U:CTMXNews ReleaseCytomX Therapeutics to Present at the Jefferies Healthcare Conference
2023-05-09 16:15U:CTMXNews ReleaseCytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update